Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 1.55%.

  • Insight Molecular Diagnostics' Return on Capital Employed fell 8600.0% to 1.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.55%, marking a year-over-year decrease of 8600.0%. This contributed to the annual value of 1.28% for FY2024, which is 9700.0% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Return on Capital Employed of 1.55% as of Q3 2025, which was down 8600.0% from 1.31% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Return on Capital Employed registered a high of 0.21% during Q4 2022, and its lowest value of 1.55% during Q3 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.52% (2022), whereas its average is 0.69%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 2800bps in 2022, then plummeted by -9900bps in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Capital Employed (Quarter) stood at 0.5% in 2021, then soared by 57bps to 0.21% in 2022, then tumbled by -66bps to 0.35% in 2023, then crashed by -280bps to 1.35% in 2024, then dropped by -15bps to 1.55% in 2025.
  • Its Return on Capital Employed was 1.55% in Q3 2025, compared to 1.31% in Q2 2025 and 1.54% in Q1 2025.